Anti-EGFR Monoclonal Antibody Mixture Sym004

Known as: Futuximab/Zatuximab, Sym004 
A mixture of two recombinant IgG1 antibodies directed against different epitopes in the epidermal growth factor receptor (EGFR) extracellular domain… (More)
National Institutes of Health

Topic mentions per year

Topic mentions per year

2010-2017
02420102017

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
PURPOSE Approved anti-EGFR antibodies cetuximab and panitumumab provide significant clinical benefit in patients with metastatic… (More)
  • table 1
  • table 2
Is this relevant?
2015
2015
UNLABELLED Tumor growth in the context of EGFR inhibitor resistance may remain EGFR-dependent and is mediated by mechanisms… (More)
Is this relevant?
2015
2015
Sym004 is a new antibody mixture to target EGFR in metastatic colorectal cancer. Preclinical data suggest efficacy in anti-EGFR… (More)
  • figure 1
Is this relevant?
2015
2015
The purpose of the trial was to assess the efficacy and tolerability of Sym004, a novel 1:1 mixture of two chimeric monoclonal… (More)
  • table 1
  • figure 2
  • table 2
  • figure 3
Is this relevant?
2013
2013
The epidermal growth factor receptor (EGFR) is a central regulator of tumor progression in a variety of human cancers. Cetuximab… (More)
Is this relevant?
2013
2013
Sym004 represents a novel EGF receptor (EGFR)-targeting approach comprising a mixture of two anti-EGFR antibodies directed… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2011
2011
The epidermal growth factor receptor (EGFR) is frequently dysregulated in human malignancies and a validated target for cancer… (More)
Is this relevant?
2011
2011
PURPOSE Sym004 is a novel therapeutic antibody mixture product comprising two unmarketed monoclonal antibodies (mAb) targeting… (More)
  • table 1
  • table 2
  • table 3
  • figure 1
  • figure 2
Is this relevant?
Highly Cited
2010
Highly Cited
2010
Epidermal growth factor receptor (EGFR) is a validated therapeutic target in cancer and EGFR antagonists with greater… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?